Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-335-5p APAF1 0.35 0.09622 -0 0.97011 miRNAWalker2 validate -0.13 0 NA
2 hsa-miR-125a-3p ATM 0.77 6.0E-5 -0.95 0 miRanda -0.11 0.00094 NA
3 hsa-miR-186-5p ATM 1.01 0 -0.95 0 mirMAP -0.13 0.00632 NA
4 hsa-miR-18a-5p ATM 3.22 0 -0.95 0 miRNAWalker2 validate; miRTarBase; MirTarget -0.12 0 23437304; 25963391; 23857602; 23229340 MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases
5 hsa-miR-324-5p ATM 2.15 0 -0.95 0 miRanda -0.16 0 NA
6 hsa-miR-339-5p ATM 1.79 0 -0.95 0 miRanda -0.16 0 NA
7 hsa-miR-421 ATM 2.1 0 -0.95 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRanda -0.12 1.0E-5 NA
8 hsa-miR-590-3p ATM 1.73 0 -0.95 0 miRanda; mirMAP -0.12 0.00045 NA
9 hsa-miR-590-5p ATM 1.46 0 -0.95 0 mirMAP -0.13 0.00013 NA
10 hsa-miR-766-3p ATM 2.7 0 -0.95 0 MirTarget -0.15 0 NA
11 hsa-miR-92a-3p ATM 1.69 0 -0.95 0 miRNAWalker2 validate -0.12 0.00206 NA
12 hsa-miR-939-5p ATM 2.15 0 -0.95 0 MirTarget -0.12 1.0E-5 NA
13 hsa-miR-101-3p BBC3 -1.48 0 0.45 0.00977 miRNATAP -0.15 0.0018 NA
14 hsa-miR-125a-5p BBC3 -0.35 0.02117 0.45 0.00977 miRNATAP -0.2 0.00029 NA
15 hsa-miR-296-5p BBC3 -0.21 0.54923 0.45 0.00977 miRNAWalker2 validate; miRTarBase; PITA; miRNATAP -0.1 2.0E-5 NA
16 hsa-let-7c-5p CASP3 -1.72 0 0.88 0 MirTarget -0.11 0 NA
17 hsa-miR-101-3p CASP3 -1.48 0 0.88 0 MirTarget -0.2 0 NA
18 hsa-miR-139-5p CASP3 -2.41 0 0.88 0 miRanda -0.13 0 NA
19 hsa-miR-140-5p CASP3 -0.89 0 0.88 0 miRanda -0.13 2.0E-5 NA
20 hsa-miR-195-3p CASP3 -1.78 0 0.88 0 MirTarget -0.11 0 NA
21 hsa-miR-26b-5p CASP3 0.3 0.04319 0.88 0 miRNAWalker2 validate -0.12 0.00027 NA
22 hsa-miR-28-5p CASP3 -0.47 0.00012 0.88 0 miRanda -0.16 0.00017 NA
23 hsa-miR-30c-5p CASP3 0.72 1.0E-5 0.88 0 miRNATAP -0.1 0.00086 NA
24 hsa-miR-374b-5p CASP3 -0.16 0.22606 0.88 0 mirMAP -0.13 0.00048 NA
25 hsa-miR-26b-5p CASP8 0.3 0.04319 0.63 0 miRNAWalker2 validate -0.12 0.00286 NA
26 hsa-miR-139-5p CCNB1 -2.41 0 3.14 0 miRanda -0.36 0 NA
27 hsa-miR-140-5p CCNB1 -0.89 0 3.14 0 miRanda -0.34 0 NA
28 hsa-let-7c-5p CCNB2 -1.72 0 4.7 0 miRNAWalker2 validate -0.28 0 NA
29 hsa-miR-23b-3p CCNB2 -0.94 0 4.7 0 miRNAWalker2 validate -0.51 0 NA
30 hsa-let-7i-5p CCND1 0.16 0.19478 0.77 0.00198 miRNATAP -0.24 0.01462 NA
31 hsa-miR-106b-5p CCND1 2.18 0 0.77 0.00198 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.15 0.01742 NA
32 hsa-miR-15b-5p CCND1 2.5 0 0.77 0.00198 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.16 0.00871 NA
33 hsa-miR-186-5p CCND1 1.01 0 0.77 0.00198 mirMAP -0.27 0.00175 NA
34 hsa-miR-193a-3p CCND1 0.42 0.05317 0.77 0.00198 MirTarget; PITA; miRanda -0.18 0.00109 NA
35 hsa-miR-195-5p CCND1 -1.82 0 0.77 0.00198 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.12 0.00793 21350001; 26631043; 25823925 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma
36 hsa-miR-19b-1-5p CCND1 0.96 0 0.77 0.00198 miRNAWalker2 validate; miRTarBase -0.14 0.01481 NA
37 hsa-miR-20a-5p CCND1 1.51 0 0.77 0.00198 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.15 0.00609 NA
38 hsa-miR-29c-3p CCND1 -1.24 0 0.77 0.00198 mirMAP -0.3 0 NA
39 hsa-miR-338-3p CCND1 0.43 0.0977 0.77 0.00198 miRNAWalker2 validate; miRTarBase; miRanda -0.1 0.02515 NA
40 hsa-miR-340-5p CCND1 1.35 0 0.77 0.00198 mirMAP -0.19 0.00589 NA
41 hsa-miR-374a-5p CCND1 -0.08 0.50964 0.77 0.00198 MirTarget -0.39 4.0E-5 27191497 microRNA 374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway; Furthermore luciferase reporter assays confirmed that miR-374a could directly reduce CCND1; We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues; High miR-374a expression with low level of CCND1 was protective factor in CRC; Together these findings indicate that miR-374a inactivates the PI3K/AKT axis by inhibiting CCND1 suppressing of colon cancer progression
42 hsa-miR-374b-5p CCND1 -0.16 0.22606 0.77 0.00198 miRNAWalker2 validate; MirTarget -0.28 0.00167 NA
43 hsa-miR-497-5p CCND1 -0.94 0.00031 0.77 0.00198 MirTarget; miRNATAP -0.11 0.0121 21350001 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer
44 hsa-let-7a-3p CCND2 1.03 0 -2.91 0 mirMAP -0.24 0.00166 20418948 MicroRNA let 7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2
45 hsa-let-7e-5p CCND2 0.82 0 -2.91 0 miRNATAP -0.38 0.00057 NA
46 hsa-let-7f-1-3p CCND2 0.99 0 -2.91 0 mirMAP -0.24 0.002 NA
47 hsa-let-7g-5p CCND2 1.16 0 -2.91 0 miRNATAP -0.34 5.0E-5 NA
48 hsa-miR-106a-5p CCND2 2.94 0 -2.91 0 miRNATAP -0.31 0 NA
49 hsa-miR-106b-5p CCND2 2.18 0 -2.91 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.67 0 NA
50 hsa-miR-10a-3p CCND2 2.65 0 -2.91 0 mirMAP -0.21 0 NA
51 hsa-miR-130b-5p CCND2 3.62 0 -2.91 0 mirMAP -0.38 0 NA
52 hsa-miR-141-3p CCND2 4.68 0 -2.91 0 MirTarget; TargetScan -0.37 0 NA
53 hsa-miR-151a-3p CCND2 0.94 0 -2.91 0 mirMAP -0.67 0 NA
54 hsa-miR-15a-5p CCND2 1.78 0 -2.91 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.62 0 NA
55 hsa-miR-15b-5p CCND2 2.5 0 -2.91 0 miRNATAP -0.73 0 NA
56 hsa-miR-16-2-3p CCND2 2.34 0 -2.91 0 mirMAP -0.5 0 NA
57 hsa-miR-16-5p CCND2 1.88 0 -2.91 0 miRNAWalker2 validate; miRNATAP -0.6 0 NA
58 hsa-miR-17-5p CCND2 2.27 0 -2.91 0 miRNAWalker2 validate; miRTarBase; TargetScan; miRNATAP -0.52 0 NA
59 hsa-miR-181a-2-3p CCND2 1.65 0 -2.91 0 mirMAP -0.33 0 NA
60 hsa-miR-182-5p CCND2 5.18 0 -2.91 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.37 0 NA
61 hsa-miR-183-5p CCND2 6.02 0 -2.91 0 miRNATAP -0.37 0 NA
62 hsa-miR-185-5p CCND2 1.98 0 -2.91 0 MirTarget; miRNATAP -0.57 0 NA
63 hsa-miR-186-5p CCND2 1.01 0 -2.91 0 mirMAP; miRNATAP -0.5 0 NA
64 hsa-miR-188-5p CCND2 1.83 0 -2.91 0 PITA; mirMAP -0.32 0 NA
65 hsa-miR-191-5p CCND2 2.25 0 -2.91 0 MirTarget -0.49 0 NA
66 hsa-miR-19a-3p CCND2 1.85 0 -2.91 0 MirTarget; miRNATAP -0.46 0 NA
67 hsa-miR-19b-3p CCND2 1.34 0 -2.91 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.51 0 NA
68 hsa-miR-200a-3p CCND2 4.84 0 -2.91 0 MirTarget -0.35 0 NA
69 hsa-miR-20a-5p CCND2 1.51 0 -2.91 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.42 0 NA
70 hsa-miR-20b-5p CCND2 3.36 0 -2.91 0 miRNATAP -0.19 0 NA
71 hsa-miR-21-3p CCND2 2.45 0 -2.91 0 mirMAP -0.29 0 NA
72 hsa-miR-301a-3p CCND2 1.94 0 -2.91 0 miRNAWalker2 validate -0.42 0 NA
73 hsa-miR-3065-3p CCND2 2.26 0 -2.91 0 MirTarget; miRNATAP -0.24 0 NA
74 hsa-miR-3065-5p CCND2 2.75 0 -2.91 0 mirMAP -0.23 0 NA
75 hsa-miR-30d-3p CCND2 0.76 4.0E-5 -2.91 0 mirMAP -0.46 0 NA
76 hsa-miR-32-3p CCND2 2.4 0 -2.91 0 mirMAP -0.37 0 NA
77 hsa-miR-320a CCND2 0.5 0.00226 -2.91 0 miRNAWalker2 validate; mirMAP; miRNATAP -0.23 0.00781 NA
78 hsa-miR-320b CCND2 1.1 0 -2.91 0 mirMAP; miRNATAP -0.31 0 NA
79 hsa-miR-320c CCND2 0.73 0.00058 -2.91 0 mirMAP; miRNATAP -0.18 0.00731 NA
80 hsa-miR-324-3p CCND2 2.35 0 -2.91 0 miRNAWalker2 validate -0.58 0 NA
81 hsa-miR-331-5p CCND2 1.36 0 -2.91 0 miRNATAP -0.42 0 NA
82 hsa-miR-33a-3p CCND2 1.39 0 -2.91 0 MirTarget -0.33 0 NA
83 hsa-miR-378a-3p CCND2 0.41 0.09788 -2.91 0 miRNAWalker2 validate -0.19 0.00115 NA
84 hsa-miR-423-5p CCND2 0.88 0 -2.91 0 miRNAWalker2 validate -0.35 0.00017 NA
85 hsa-miR-429 CCND2 5.04 0 -2.91 0 miRNATAP -0.35 0 NA
86 hsa-miR-486-5p CCND2 0.63 0.03561 -2.91 0 miRNATAP -0.13 0.00611 NA
87 hsa-miR-500a-5p CCND2 0.8 4.0E-5 -2.91 0 mirMAP -0.24 0.00106 NA
88 hsa-miR-501-5p CCND2 1.63 0 -2.91 0 PITA; mirMAP; miRNATAP -0.39 0 NA
89 hsa-miR-548v CCND2 1.7 0 -2.91 0 MirTarget -0.23 0 NA
90 hsa-miR-550a-5p CCND2 1.69 0 -2.91 0 MirTarget -0.47 0 NA
91 hsa-miR-577 CCND2 3.23 0 -2.91 0 PITA; mirMAP -0.15 0 NA
92 hsa-miR-589-3p CCND2 1.7 0 -2.91 0 mirMAP -0.3 0 NA
93 hsa-miR-590-3p CCND2 1.73 0 -2.91 0 miRanda; mirMAP -0.35 0 NA
94 hsa-miR-590-5p CCND2 1.46 0 -2.91 0 mirMAP -0.46 0 NA
95 hsa-miR-616-5p CCND2 1.97 0 -2.91 0 mirMAP -0.3 0 NA
96 hsa-miR-660-5p CCND2 0.21 0.2672 -2.91 0 mirMAP -0.2 0.00979 NA
97 hsa-miR-7-1-3p CCND2 1.84 0 -2.91 0 mirMAP -0.35 0 NA
98 hsa-miR-877-5p CCND2 3.92 0 -2.91 0 miRNAWalker2 validate -0.36 0 NA
99 hsa-miR-9-3p CCND2 2.21 0 -2.91 0 MirTarget; mirMAP; miRNATAP -0.16 0 NA
100 hsa-miR-93-5p CCND2 2.58 0 -2.91 0 miRNATAP -0.66 0 NA
101 hsa-miR-96-5p CCND2 5.73 0 -2.91 0 TargetScan; miRNATAP -0.38 0 NA
102 hsa-miR-125b-5p CCNE1 -1.42 0 3.88 0 miRNAWalker2 validate -0.25 2.0E-5 NA
103 hsa-miR-195-5p CCNE1 -1.82 0 3.88 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.5 0 24402230 Furthermore through qPCR and western blot assays we showed that overexpression of miR-195-5p reduced CCNE1 mRNA and protein levels respectively
104 hsa-miR-26a-5p CCNE1 -0.63 0 3.88 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.29 0.02122 22094936 Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen
105 hsa-miR-424-5p CCNE1 -2.23 0 3.88 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.36 0 NA
106 hsa-miR-497-5p CCNE1 -0.94 0.00031 3.88 0 MirTarget; miRNATAP -0.42 0 24112607; 25909221; 24909281 Western blot assays confirmed that overexpression of miR-497 reduced cyclin E1 protein levels; Inhibited cellular growth suppressed cellular migration and invasion and G1 cell cycle arrest were observed upon overexpression of miR-497 in cells possibly by targeting cyclin E1;The effect of simultaneous overexpression of miR-497 and miR-34a on the inhibition of cell proliferation colony formation and tumor growth and the downregulation of cyclin E1 was stronger than the effect of each miRNA alone; The synergistic actions of miR-497 and miR-34a partly correlated with cyclin E1 levels; These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a which synergistically retard the growth of human lung cancer cells;miR 497 suppresses proliferation of human cervical carcinoma HeLa cells by targeting cyclin E1; Furthermore the target effect of miR-497 on the CCNE1 was identified by dual-luciferase reporter assay system qRT-PCR and Western blotting; Over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting CCNE1
107 hsa-miR-126-3p CCNE2 -0.24 0.10958 2.32 0 miRNAWalker2 validate -0.24 0.00698 NA
108 hsa-miR-140-5p CCNE2 -0.89 0 2.32 0 miRanda -0.41 0 NA
109 hsa-miR-26a-5p CCNE2 -0.63 0 2.32 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.62 0 24116110; 21901171 The loss of miR 26a mediated post transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival; The in vitro and in vivo assays showed that overexpression of miR-26a resulted in cell cycle arrest inhibited cell proliferation and decreased tumor growth which was associated with cyclin E2 downregulation;We also show that enforced expression of miR-26a in AML cells is able to inhibit cell cycle progression by downregulating cyclin E2 expression
110 hsa-miR-26b-5p CCNE2 0.3 0.04319 2.32 0 miRNATAP -0.26 0.00373 NA
111 hsa-miR-30a-5p CCNE2 0.2 0.42032 2.32 0 miRNATAP -0.18 0.00073 NA
112 hsa-let-7e-5p CCNG1 0.82 0 -0.68 0 miRNAWalker2 validate -0.12 0.02355 NA
113 hsa-miR-142-5p CCNG1 1.99 0 -0.68 0 mirMAP -0.11 1.0E-5 NA
114 hsa-miR-21-5p CCNG1 1.51 0 -0.68 0 miRNAWalker2 validate -0.1 0.00756 NA
115 hsa-miR-23a-3p CCNG1 1.08 0 -0.68 0 MirTarget; miRNATAP -0.21 0 NA
116 hsa-miR-24-3p CCNG1 0.86 0 -0.68 0 miRNAWalker2 validate -0.23 0 NA
117 hsa-miR-27a-3p CCNG1 1.21 0 -0.68 0 MirTarget; miRNATAP -0.21 0 NA
118 hsa-miR-335-3p CCNG1 1.32 0 -0.68 0 MirTarget; mirMAP -0.11 0.0001 NA
119 hsa-miR-339-5p CCNG1 1.79 0 -0.68 0 miRanda -0.13 2.0E-5 NA
120 hsa-miR-590-3p CCNG1 1.73 0 -0.68 0 miRanda -0.14 2.0E-5 NA
121 hsa-miR-590-5p CCNG1 1.46 0 -0.68 0 miRanda -0.14 6.0E-5 NA
122 hsa-miR-96-5p CCNG1 5.73 0 -0.68 0 MirTarget; TargetScan -0.11 0 NA
123 hsa-let-7a-3p CCNG2 1.03 0 -0.24 0.07462 MirTarget; mirMAP -0.14 4.0E-5 NA
124 hsa-let-7f-1-3p CCNG2 0.99 0 -0.24 0.07462 MirTarget; mirMAP -0.13 0.0002 NA
125 hsa-miR-142-5p CCNG2 1.99 0 -0.24 0.07462 MirTarget; miRNATAP -0.14 0 NA
126 hsa-miR-16-2-3p CCNG2 2.34 0 -0.24 0.07462 mirMAP -0.11 0.00042 NA
127 hsa-miR-26a-2-3p CCNG2 0.1 0.58757 -0.24 0.07462 mirMAP -0.11 0.00397 NA
128 hsa-miR-26a-5p CCNG2 -0.63 0 -0.24 0.07462 mirMAP -0.15 0.00605 NA
129 hsa-miR-26b-3p CCNG2 0.54 0.00102 -0.24 0.07462 MirTarget -0.13 0.00089 NA
130 hsa-miR-26b-5p CCNG2 0.3 0.04319 -0.24 0.07462 mirMAP -0.2 0 NA
131 hsa-miR-331-5p CCNG2 1.36 0 -0.24 0.07462 miRNATAP -0.15 4.0E-5 NA
132 hsa-miR-335-5p CCNG2 0.35 0.09622 -0.24 0.07462 miRNAWalker2 validate; mirMAP -0.16 0 NA
133 hsa-miR-342-3p CCNG2 0.91 0 -0.24 0.07462 miRanda -0.23 0 NA
134 hsa-miR-374b-5p CCNG2 -0.16 0.22606 -0.24 0.07462 mirMAP -0.19 7.0E-5 NA
135 hsa-miR-590-3p CCNG2 1.73 0 -0.24 0.07462 miRanda; mirMAP -0.13 0.0001 NA
136 hsa-miR-590-5p CCNG2 1.46 0 -0.24 0.07462 mirMAP -0.15 2.0E-5 NA
137 hsa-miR-127-3p CD82 -1.35 0 0.67 0.00603 miRanda -0.22 0 NA
138 hsa-miR-140-5p CDK2 -0.89 0 0.53 5.0E-5 miRanda -0.18 0 NA
139 hsa-miR-23b-3p CDK2 -0.94 0 0.53 5.0E-5 miRNAWalker2 validate -0.12 0.00204 NA
140 hsa-miR-26b-5p CDK2 0.3 0.04319 0.53 5.0E-5 miRNAWalker2 validate -0.13 0.00126 NA
141 hsa-miR-195-5p CDK4 -1.82 0 0.3 0.00478 miRNAWalker2 validate; miRTarBase -0.12 0 NA
142 hsa-let-7a-3p CDK6 1.03 0 -0.99 0.0001 miRNATAP -0.3 0 NA
143 hsa-let-7a-5p CDK6 0.1 0.43289 -0.99 0.0001 miRNAWalker2 validate; miRTarBase; TargetScan -0.58 0 NA
144 hsa-let-7b-3p CDK6 0.35 0.07056 -0.99 0.0001 miRNATAP -0.26 3.0E-5 NA
145 hsa-let-7b-5p CDK6 -0.07 0.65185 -0.99 0.0001 miRNAWalker2 validate; miRTarBase -0.37 0 NA
146 hsa-miR-106b-5p CDK6 2.18 0 -0.99 0.0001 mirMAP -0.15 0.01871 NA
147 hsa-miR-107 CDK6 1.81 0 -0.99 0.0001 miRNAWalker2 validate; miRTarBase; PITA; miRNATAP -0.2 0.00392 19407485; 22491216; 21264532; 19688090 Enforced expression of miR-107 in MiaPACA-2 and PANC-1 cells downregulated in vitro growth and this was associated with repression of the putative miR-107 target cyclin-dependent kinase 6 thereby providing a functional basis for the epigenetic inactivation of this miRNA in pancreatic cancer;Levels of known miR-107 targets protein kinase Cε PKCε cyclin-dependent kinase 6 CDK6 and hypoxia-inducible factor 1-β HIF1-β decreased following NP/pre-miR-107 treatment;We have identified miR-107 as a potential regulator of CDK6 expression; A bioinformatics search revealed a putative target site for miR-107 within the CDK6 3' untranslated region; Expression of miR-107 in gastric cancer cell lines was found inversely correlated with CDK6 expression; miR-107 could significantly suppress CDK6 3' UTR luciferase reporter activity and this effect was not detectable when the putative 3' UTR target site was mutated; Consistent with the results of the reporter assay ectopic expression of miR-107 reduced both mRNA and protein expression levels of CDK6 inhibited proliferation induced G1 cell cycle arrest and blocked invasion of the gastric cancer cells; Our results suggest that miR-107 may have a tumor suppressor function by directly targeting CDK6 to inhibit the proliferation and invasion activities of gastric cancer cells;Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6
148 hsa-miR-1254 CDK6 2.69 0 -0.99 0.0001 PITA; miRNATAP -0.11 0.01773 NA
149 hsa-miR-141-3p CDK6 4.68 0 -0.99 0.0001 TargetScan; miRNATAP -0.2 0 NA
150 hsa-miR-148b-3p CDK6 1.81 0 -0.99 0.0001 mirMAP -0.36 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF CELL CYCLE 29 949 1.313e-26 6.111e-23
2 CELL CYCLE 29 1316 1.362e-22 3.168e-19
3 POSITIVE REGULATION OF CELL DEATH 22 605 3.397e-21 3.951e-18
4 NEGATIVE REGULATION OF CELL CYCLE 20 433 3.174e-21 3.951e-18
5 CELL CYCLE PROCESS 26 1081 7.363e-21 6.852e-18
6 MITOTIC CELL CYCLE 23 766 2.35e-20 1.822e-17
7 REGULATION OF CELL DEATH 28 1472 5.807e-20 3.86e-17
8 REGULATION OF CELL CYCLE ARREST 13 108 2.597e-19 1.51e-16
9 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 12 98 5.754e-18 2.975e-15
10 CELL DEATH 23 1001 8.923e-18 4.152e-15
11 G1 DNA DAMAGE CHECKPOINT 11 73 1.414e-17 4.886e-15
12 POSITIVE REGULATION OF CELL CYCLE PROCESS 15 247 1.177e-17 4.886e-15
13 RESPONSE TO ABIOTIC STIMULUS 23 1024 1.47e-17 4.886e-15
14 CELL CYCLE CHECKPOINT 14 194 1.468e-17 4.886e-15
15 CELL CYCLE PHASE TRANSITION 15 255 1.901e-17 5.898e-15
16 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 26 1492 2.192e-17 6.374e-15
17 POSITIVE REGULATION OF CELL CYCLE 16 332 3.233e-17 8.849e-15
18 NEGATIVE REGULATION OF CELL CYCLE PROCESS 14 214 5.881e-17 1.52e-14
19 POSITIVE REGULATION OF CELL CYCLE ARREST 11 85 8.308e-17 2.035e-14
20 SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 12 127 1.451e-16 3.376e-14
21 REGULATION OF MITOTIC CELL CYCLE 17 468 3.089e-16 6.843e-14
22 MITOTIC DNA INTEGRITY CHECKPOINT 11 100 5.376e-16 1.137e-13
23 REGULATION OF PROTEIN MODIFICATION PROCESS 26 1710 6.088e-16 1.232e-13
24 REGULATION OF TRANSFERASE ACTIVITY 21 946 7.915e-16 1.44e-13
25 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 12 146 8.046e-16 1.44e-13
26 DNA INTEGRITY CHECKPOINT 12 146 8.046e-16 1.44e-13
27 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 12 147 8.747e-16 1.491e-13
28 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 13 199 8.973e-16 1.491e-13
29 APOPTOTIC SIGNALING PATHWAY 14 289 3.924e-15 6.296e-13
30 CELLULAR RESPONSE TO STRESS 24 1565 1.202e-14 1.865e-12
31 REGULATION OF CELL CYCLE PHASE TRANSITION 14 321 1.675e-14 2.514e-12
32 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 10 96 2.258e-14 3.183e-12
33 MITOTIC CELL CYCLE CHECKPOINT 11 139 2.219e-14 3.183e-12
34 REGULATION OF PHOSPHORUS METABOLIC PROCESS 24 1618 2.518e-14 3.446e-12
35 INTRINSIC APOPTOTIC SIGNALING PATHWAY 11 152 6.012e-14 7.993e-12
36 REGULATION OF CELL CYCLE PROCESS 16 558 1.077e-13 1.391e-11
37 REPLICATIVE SENESCENCE 6 12 1.263e-13 1.588e-11
38 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 15 470 1.585e-13 1.941e-11
39 RESPONSE TO OXYGEN LEVELS 13 311 2.867e-13 3.42e-11
40 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 17 720 3.554e-13 4.135e-11
41 AGING 12 264 9.959e-13 1.13e-10
42 REGULATION OF KINASE ACTIVITY 17 776 1.183e-12 1.301e-10
43 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 9 95 1.203e-12 1.301e-10
44 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 9 97 1.458e-12 1.542e-10
45 INTRACELLULAR SIGNAL TRANSDUCTION 22 1572 1.615e-12 1.67e-10
46 REGULATION OF APOPTOTIC SIGNALING PATHWAY 13 363 2.037e-12 2.061e-10
47 CELL CYCLE ARREST 10 154 2.777e-12 2.749e-10
48 CELL CYCLE G1 S PHASE TRANSITION 9 111 5.028e-12 4.775e-10
49 G1 S TRANSITION OF MITOTIC CELL CYCLE 9 111 5.028e-12 4.775e-10
50 ZYMOGEN ACTIVATION 9 112 5.458e-12 5.079e-10
51 REGULATION OF CELL PROLIFERATION 21 1496 6.142e-12 5.603e-10
52 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 10 171 7.917e-12 7.084e-10
53 RESPONSE TO DRUG 13 431 1.757e-11 1.542e-09
54 CELL DIVISION 13 460 3.95e-11 3.404e-09
55 POSITIVE REGULATION OF PROTEOLYSIS 12 363 4.13e-11 3.494e-09
56 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 21 1656 4.212e-11 3.5e-09
57 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 18 1135 4.7e-11 3.836e-09
58 RESPONSE TO IONIZING RADIATION 9 145 5.681e-11 4.557e-09
59 REGULATION OF PROTEOLYSIS 15 711 5.808e-11 4.58e-09
60 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 10 213 6.982e-11 5.415e-09
61 POSITIVE REGULATION OF CATALYTIC ACTIVITY 20 1518 7.566e-11 5.772e-09
62 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 9 154 9.76e-11 7.208e-09
63 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 16 876 9.679e-11 7.208e-09
64 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 17 1036 1.132e-10 8.101e-09
65 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 17 1036 1.132e-10 8.101e-09
66 REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 9 162 1.536e-10 1.083e-08
67 POSITIVE REGULATION OF MOLECULAR FUNCTION 21 1791 1.826e-10 1.268e-08
68 CELL AGING 7 67 2.266e-10 1.551e-08
69 CELLULAR RESPONSE TO ABIOTIC STIMULUS 10 263 5.493e-10 3.705e-08
70 CELL CYCLE G2 M PHASE TRANSITION 8 138 1.252e-09 8.325e-08
71 DNA METABOLIC PROCESS 14 758 1.632e-09 1.07e-07
72 REGULATION OF PEPTIDASE ACTIVITY 11 392 1.682e-09 1.087e-07
73 NEGATIVE REGULATION OF CELL PROLIFERATION 13 643 2.381e-09 1.518e-07
74 RESPONSE TO RADIATION 11 413 2.901e-09 1.824e-07
75 REGULATION OF RESPONSE TO STRESS 18 1468 3.011e-09 1.868e-07
76 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 6 55 3.667e-09 2.245e-07
77 REGENERATION 8 161 4.251e-09 2.569e-07
78 REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 6 59 5.658e-09 3.375e-07
79 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 10 351 8.824e-09 5.132e-07
80 RESPONSE TO X RAY 5 30 8.754e-09 5.132e-07
81 RESPONSE TO OXYGEN CONTAINING COMPOUND 17 1381 9.099e-09 5.227e-07
82 CELLULAR RESPONSE TO EXTERNAL STIMULUS 9 264 1.136e-08 6.446e-07
83 PROTEIN MATURATION 9 265 1.174e-08 6.554e-07
84 RESPONSE TO ALCOHOL 10 362 1.183e-08 6.554e-07
85 RESPONSE TO LIPID 14 888 1.231e-08 6.738e-07
86 RESPONSE TO STEROID HORMONE 11 497 1.968e-08 1.045e-06
87 NEURON APOPTOTIC PROCESS 5 35 1.976e-08 1.045e-06
88 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 15 1087 1.948e-08 1.045e-06
89 PROTEIN STABILIZATION 7 131 2.592e-08 1.355e-06
90 DNA REPLICATION 8 208 3.159e-08 1.633e-06
91 REGULATION OF FIBROBLAST PROLIFERATION 6 81 3.917e-08 2.003e-06
92 POSITIVE REGULATION OF CELL COMMUNICATION 17 1532 4.236e-08 2.143e-06
93 ORGAN REGENERATION 6 83 4.539e-08 2.25e-06
94 RESPONSE TO ESTROGEN 8 218 4.546e-08 2.25e-06
95 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 13 829 4.876e-08 2.388e-06
96 REGULATION OF PROTEIN STABILITY 8 221 5.053e-08 2.449e-06
97 RESPONSE TO ESTRADIOL 7 146 5.48e-08 2.629e-06
98 REGULATION OF CELLULAR RESPONSE TO STRESS 12 691 5.853e-08 2.779e-06
99 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 7 153 7.562e-08 3.554e-06
100 RESPONSE TO METAL ION 9 333 8.363e-08 3.891e-06
101 RESPONSE TO EXTERNAL STIMULUS 18 1821 8.661e-08 3.99e-06
102 NEGATIVE REGULATION OF CELL DEATH 13 872 8.795e-08 4.012e-06
103 NEURON DEATH 5 47 9.14e-08 4.129e-06
104 RESPONSE TO TOXIC SUBSTANCE 8 241 9.855e-08 4.409e-06
105 REGULATION OF DNA METABOLIC PROCESS 9 340 9.983e-08 4.424e-06
106 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 6 98 1.232e-07 5.408e-06
107 NEGATIVE REGULATION OF CELL CYCLE ARREST 4 20 1.375e-07 5.98e-06
108 NEGATIVE REGULATION OF MOLECULAR FUNCTION 14 1079 1.399e-07 6.026e-06
109 RESPONSE TO ORGANIC CYCLIC COMPOUND 13 917 1.575e-07 6.725e-06
110 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 5 53 1.692e-07 7.091e-06
111 INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 5 53 1.692e-07 7.091e-06
112 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 11 616 1.736e-07 7.211e-06
113 POSITIVE REGULATION OF RESPONSE TO STIMULUS 18 1929 2.077e-07 8.554e-06
114 RESPONSE TO KETONE 7 182 2.474e-07 1.01e-05
115 HISTONE PHOSPHORYLATION 4 25 3.559e-07 1.44e-05
116 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 8 289 3.944e-07 1.582e-05
117 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 7 200 4.684e-07 1.863e-05
118 RESPONSE TO UV 6 126 5.481e-07 2.161e-05
119 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 4 28 5.73e-07 2.241e-05
120 NEGATIVE REGULATION OF PHOSPHORYLATION 9 422 6.161e-07 2.389e-05
121 RESPONSE TO MECHANICAL STIMULUS 7 210 6.507e-07 2.502e-05
122 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 6.636e-07 2.51e-05
123 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 6.636e-07 2.51e-05
124 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 5 71 7.431e-07 2.788e-05
125 NEGATIVE REGULATION OF B CELL ACTIVATION 4 30 7.643e-07 2.822e-05
126 NEGATIVE REGULATION OF CELL MATRIX ADHESION 4 30 7.643e-07 2.822e-05
127 RESPONSE TO ENDOGENOUS STIMULUS 15 1450 8.319e-07 3.048e-05
128 CELLULAR RESPONSE TO RADIATION 6 137 8.966e-07 3.259e-05
129 RESPONSE TO HORMONE 12 893 9.189e-07 3.314e-05
130 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 32 9.994e-07 3.577e-05
131 CELLULAR RESPONSE TO OXYGEN LEVELS 6 143 1.153e-06 4.094e-05
132 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 5 79 1.268e-06 4.47e-05
133 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 4 34 1.284e-06 4.493e-05
134 CELLULAR RESPONSE TO MECHANICAL STIMULUS 5 80 1.35e-06 4.688e-05
135 POSITIVE REGULATION OF MAPK CASCADE 9 470 1.505e-06 5.186e-05
136 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 36 1.626e-06 5.521e-05
137 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 10 616 1.625e-06 5.521e-05
138 RESPONSE TO INORGANIC SUBSTANCE 9 479 1.759e-06 5.931e-05
139 POSITIVE REGULATION OF KINASE ACTIVITY 9 482 1.852e-06 6.199e-05
140 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 8 360 2.053e-06 6.823e-05
141 NEGATIVE REGULATION OF KINASE ACTIVITY 7 250 2.085e-06 6.833e-05
142 REGULATION OF GROWTH 10 633 2.074e-06 6.833e-05
143 ACTIVATION OF MAPKKK ACTIVITY 3 11 2.112e-06 6.872e-05
144 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 14 1360 2.276e-06 7.355e-05
145 REGULATION OF CELL MATRIX ADHESION 5 90 2.424e-06 7.78e-05
146 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 43 3.364e-06 0.0001072
147 PROTEOLYSIS 13 1208 3.536e-06 0.0001119
148 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 13 3.648e-06 0.0001139
149 RESPONSE TO COBALT ION 3 13 3.648e-06 0.0001139
150 RESPONSE TO CORTICOSTEROID 6 176 3.851e-06 0.0001195
151 RESPONSE TO NITROGEN COMPOUND 11 859 4.524e-06 0.0001394
152 POSITIVE REGULATION OF P38MAPK CASCADE 3 14 4.636e-06 0.000141
153 DETERMINATION OF ADULT LIFESPAN 3 14 4.636e-06 0.000141
154 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 9 541 4.752e-06 0.0001427
155 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 9 541 4.752e-06 0.0001427
156 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 4 47 4.828e-06 0.000144
157 REGULATION OF CELLULAR PROTEIN LOCALIZATION 9 552 5.593e-06 0.0001658
158 NEGATIVE REGULATION OF B CELL PROLIFERATION 3 15 5.785e-06 0.0001704
159 RESPONSE TO GAMMA RADIATION 4 50 6.201e-06 0.0001815
160 CELLULAR RESPONSE TO IONIZING RADIATION 4 52 7.264e-06 0.0002112
161 REGULATION OF CATABOLIC PROCESS 10 731 7.431e-06 0.0002148
162 NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION 4 53 7.843e-06 0.0002253
163 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 16 1977 8.125e-06 0.0002319
164 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 4 54 8.455e-06 0.0002399
165 POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 17 8.616e-06 0.000243
166 RESPONSE TO EXTRACELLULAR STIMULUS 8 441 9.132e-06 0.0002545
167 REGULATION OF B CELL PROLIFERATION 4 55 9.102e-06 0.0002545
168 REGULATION OF B CELL ACTIVATION 5 121 1.037e-05 0.0002873
169 PROTEIN PHOSPHORYLATION 11 944 1.107e-05 0.0003049
170 POSITIVE REGULATION OF MITOTIC CELL CYCLE 5 123 1.123e-05 0.0003075
171 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 5 126 1.263e-05 0.0003437
172 REGULATION OF MITOCHONDRION ORGANIZATION 6 218 1.311e-05 0.0003547
173 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 5 128 1.363e-05 0.0003667
174 POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 3 20 1.437e-05 0.0003843
175 DNA REPAIR 8 480 1.686e-05 0.0004483
176 NEGATIVE REGULATION OF CELL COMMUNICATION 12 1192 1.788e-05 0.0004727
177 RESPONSE TO ETHANOL 5 136 1.828e-05 0.0004806
178 CIRCADIAN RHYTHM 5 137 1.894e-05 0.0004924
179 CELLULAR RESPONSE TO UV 4 66 1.887e-05 0.0004924
180 RESPONSE TO ENDOPLASMIC RETICULUM STRESS 6 233 1.911e-05 0.000494
181 POSITIVE REGULATION OF PROTEIN OLIGOMERIZATION 3 22 1.935e-05 0.0004947
182 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 3 22 1.935e-05 0.0004947
183 POSITIVE REGULATION OF NEURON DEATH 4 67 2.003e-05 0.0005093
184 NEGATIVE REGULATION OF GROWTH 6 236 2.054e-05 0.0005194
185 ORGANELLE FISSION 8 496 2.134e-05 0.0005366
186 RESPONSE TO INCREASED OXYGEN LEVELS 3 23 2.221e-05 0.0005527
187 RESPONSE TO HYPEROXIA 3 23 2.221e-05 0.0005527
188 MITOTIC NUCLEAR DIVISION 7 361 2.294e-05 0.0005678
189 REGULATION OF MAPK CASCADE 9 660 2.328e-05 0.0005704
190 RAS PROTEIN SIGNAL TRANSDUCTION 5 143 2.329e-05 0.0005704
191 REGULATION OF MEMBRANE PERMEABILITY 4 70 2.383e-05 0.0005806
192 PHOSPHORYLATION 12 1228 2.404e-05 0.0005827
193 REGULATION OF EXECUTION PHASE OF APOPTOSIS 3 24 2.534e-05 0.000611
194 REGULATION OF NEURON DEATH 6 252 2.97e-05 0.0007123
195 RESPONSE TO CORTICOSTERONE 3 26 3.245e-05 0.0007703
196 REGULATION OF P38MAPK CASCADE 3 26 3.245e-05 0.0007703
197 POSITIVE REGULATION OF GENE EXPRESSION 14 1733 3.663e-05 0.0008651
198 RESPONSE TO BIOTIC STIMULUS 10 886 3.906e-05 0.0009179
199 REGULATION OF PROTEIN CATABOLIC PROCESS 7 393 3.943e-05 0.0009219
200 REGULATION OF DNA REPLICATION 5 161 4.113e-05 0.0009568
201 REGULATION OF NUCLEAR DIVISION 5 163 4.362e-05 0.00101
202 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR 3 30 5.033e-05 0.001155
203 RESPONSE TO CARBOHYDRATE 5 168 5.038e-05 0.001155
204 REGULATION OF HYDROLASE ACTIVITY 12 1327 5.153e-05 0.001175
205 ACTIVATION OF PROTEIN KINASE ACTIVITY 6 279 5.24e-05 0.001189
206 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 86 5.367e-05 0.001206
207 RESPONSE TO LIGHT STIMULUS 6 280 5.346e-05 0.001206
208 MULTICELLULAR ORGANISM AGING 3 31 5.563e-05 0.001244
209 REGULATION OF CELL SUBSTRATE ADHESION 5 173 5.791e-05 0.001289
210 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 8 573 5.938e-05 0.001316
211 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS 3 32 6.128e-05 0.001351
212 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 6.696e-05 0.001456
213 REGULATION OF PROTEIN EXPORT FROM NUCLEUS 3 33 6.729e-05 0.001456
214 CELLULAR SENESCENCE 3 33 6.729e-05 0.001456
215 REGULATION OF CELL AGING 3 33 6.729e-05 0.001456
216 MITOCHONDRIAL MEMBRANE ORGANIZATION 4 92 6.988e-05 0.001505
217 T CELL HOMEOSTASIS 3 34 7.368e-05 0.001573
218 PROTEIN KINASE B SIGNALING 3 34 7.368e-05 0.001573
219 RHYTHMIC PROCESS 6 298 7.545e-05 0.001603
220 MITOCHONDRION ORGANIZATION 8 594 7.639e-05 0.001616
221 REGULATION OF PROTEIN OLIGOMERIZATION 3 35 8.045e-05 0.001679
222 RESPONSE TO MINERALOCORTICOID 3 35 8.045e-05 0.001679
223 REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES 3 35 8.045e-05 0.001679
224 REGULATION OF ORGANELLE ORGANIZATION 11 1178 8.485e-05 0.001763
225 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 3 36 8.762e-05 0.001812
226 RESPONSE TO NUTRIENT 5 191 9.25e-05 0.001904
227 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 4 99 9.299e-05 0.001906
228 REGULATION OF NEURON APOPTOTIC PROCESS 5 192 9.48e-05 0.001935
229 REGULATION OF INTRACELLULAR TRANSPORT 8 621 0.000104 0.002114
230 EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 3 39 0.0001116 0.002257
231 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 7 465 0.0001133 0.002276
232 RESPONSE TO MOLECULE OF BACTERIAL ORIGIN 6 321 0.0001135 0.002276
233 REGULATION OF LEUKOCYTE PROLIFERATION 5 206 0.0001319 0.002635
234 REGULATION OF CELL ACTIVATION 7 484 0.0001452 0.002887
235 REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 44 0.0001603 0.003175
236 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 5 220 0.0001793 0.003535
237 RESPONSE TO OXIDATIVE STRESS 6 352 0.0001874 0.003679
238 NEGATIVE REGULATION OF CELL ADHESION 5 223 0.000191 0.003733
239 RESPONSE TO ANTIBIOTIC 3 47 0.0001953 0.003803
240 REGULATION OF SMOOTH MUSCLE CELL MIGRATION 3 49 0.0002212 0.004288
241 LYMPHOCYTE HOMEOSTASIS 3 50 0.0002349 0.004535
242 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 13 1805 0.0002394 0.004602
243 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 6 370 0.0002452 0.004695
244 RESPONSE TO BACTERIUM 7 528 0.0002475 0.00472
245 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 6 372 0.0002524 0.004793
246 POSITIVE REGULATION OF HYDROLASE ACTIVITY 9 905 0.0002611 0.004939
247 POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 3 52 0.000264 0.004973
248 REGULATION OF LIGASE ACTIVITY 4 130 0.0002657 0.004986
249 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 3 53 0.0002794 0.00522
250 EXECUTION PHASE OF APOPTOSIS 3 55 0.0003118 0.005803
251 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 10 1142 0.000317 0.005876
252 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 10 1152 0.0003399 0.006275
253 REGULATION OF THYMOCYTE APOPTOTIC PROCESS 2 12 0.0003666 0.006689
254 DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS 2 12 0.0003666 0.006689
255 POSITIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 12 0.0003666 0.006689
256 REGULATION OF PROTEIN LOCALIZATION 9 950 0.0003734 0.006787
257 REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS 3 59 0.0003838 0.006948
258 REGULATION OF IMMUNE SYSTEM PROCESS 11 1403 0.0003927 0.007082
259 REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY 4 145 0.0004026 0.00719
260 REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 4 145 0.0004026 0.00719
261 LEUKOCYTE HOMEOSTASIS 3 60 0.0004033 0.00719
262 POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 2 13 0.0004326 0.007524
263 REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS 4 148 0.000435 0.007524
264 PEPTIDYL SERINE MODIFICATION 4 148 0.000435 0.007524
265 PROTEIN CATABOLIC PROCESS 7 579 0.0004319 0.007524
266 MITOTIC CELL CYCLE ARREST 2 13 0.0004326 0.007524
267 REGULATION OF HISTONE PHOSPHORYLATION 2 13 0.0004326 0.007524
268 RESPONSE TO TEMPERATURE STIMULUS 4 148 0.000435 0.007524
269 RESPONSE TO TRANSITION METAL NANOPARTICLE 4 148 0.000435 0.007524
270 POSITIVE REGULATION OF CHROMOSOME ORGANIZATION 4 150 0.0004576 0.007887
271 REGULATION OF CELL DIVISION 5 272 0.0004761 0.008175
272 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 152 0.0004811 0.0082
273 REGULATION OF CHROMATIN ORGANIZATION 4 152 0.0004811 0.0082
274 REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS 5 274 0.0004923 0.00836
275 MITOCHONDRIAL DNA METABOLIC PROCESS 2 14 0.0005039 0.008465
276 REGULATION OF FIBRINOLYSIS 2 14 0.0005039 0.008465
277 REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS 2 14 0.0005039 0.008465
278 REGULATION OF RESPONSE TO OXIDATIVE STRESS 3 65 0.0005105 0.008544
279 REGULATION OF CHROMOSOME ORGANIZATION 5 278 0.0005258 0.008769
280 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 7 602 0.0005449 0.009055
281 NEGATIVE REGULATION OF CELL ACTIVATION 4 158 0.0005567 0.009174
282 RESPONSE TO PURINE CONTAINING COMPOUND 4 158 0.0005567 0.009174
283 REGULATION OF SISTER CHROMATID SEGREGATION 3 67 0.000558 0.009174
284 DENTATE GYRUS DEVELOPMENT 2 15 0.0005805 0.009318
285 PROTEIN OLIGOMERIZATION 6 434 0.0005724 0.009318
286 REGULATION OF JNK CASCADE 4 159 0.00057 0.009318
287 RESPONSE TO VITAMIN E 2 15 0.0005805 0.009318
288 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 8 801 0.000582 0.009318
289 POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS 2 15 0.0005805 0.009318
290 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 3 68 0.0005827 0.009318
291 DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION RESULTING IN TRANSCRIPTION 2 15 0.0005805 0.009318
292 REGULATION OF EPITHELIAL CELL PROLIFERATION 5 285 0.0005885 0.009378
293 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 6 437 0.0005934 0.009424
294 NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION 3 69 0.0006082 0.009626
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY 7 28 3.309e-13 3.074e-10
2 KINASE BINDING 12 606 1.381e-08 5.255e-06
3 CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 5 34 1.697e-08 5.255e-06
4 ENZYME BINDING 18 1737 4.195e-08 9.744e-06
5 CYCLIN BINDING 4 19 1.102e-07 2.048e-05
6 KINASE REGULATOR ACTIVITY 7 186 2.867e-07 4.439e-05
7 PROTEIN COMPLEX BINDING 12 935 1.489e-06 0.0001976
8 PROTEIN KINASE ACTIVITY 10 640 2.289e-06 0.0002658
9 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 3 12 2.811e-06 0.0002902
10 MACROMOLECULAR COMPLEX BINDING 14 1399 3.174e-06 0.0002948
11 KINASE ACTIVITY 11 842 3.736e-06 0.0003155
12 PROTEIN SERINE THREONINE KINASE ACTIVITY 8 445 9.752e-06 0.000755
13 HISTONE KINASE ACTIVITY 3 19 1.224e-05 0.0008745
14 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 11 992 1.762e-05 0.001169
15 P53 BINDING 4 67 2.003e-05 0.00124
16 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 3 30 5.033e-05 0.002922
17 ENZYME REGULATOR ACTIVITY 10 959 7.602e-05 0.004154
18 PROTEASE BINDING 4 104 0.0001126 0.005811
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX 7 31 7.31e-13 4.269e-10
2 PROTEIN KINASE COMPLEX 7 90 1.868e-09 5.454e-07
3 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 8 237 8.665e-08 1.687e-05
4 CATALYTIC COMPLEX 12 1038 4.401e-06 0.0006425
5 CHROMOSOME 10 880 3.687e-05 0.004307

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 p53_signaling_pathway_hsa04115 47 68 1.746e-124 9.078e-123
2 Cellular_senescence_hsa04218 21 160 4.404e-32 1.145e-30
3 Cell_cycle_hsa04110 18 124 3.174e-28 5.501e-27
4 FoxO_signaling_pathway_hsa04068 13 132 3.906e-18 5.078e-17
5 Apoptosis_hsa04210 12 138 4.033e-16 4.195e-15
6 PI3K_Akt_signaling_pathway_hsa04151 12 352 2.891e-11 2.506e-10
7 Apoptosis_multiple_species_hsa04215 5 33 1.45e-08 1.077e-07
8 Oocyte_meiosis_hsa04114 6 124 4.987e-07 3.242e-06
9 MAPK_signaling_pathway_hsa04010 7 295 6.206e-06 3.586e-05
10 Hippo_signaling_pathway_hsa04390 5 154 3.325e-05 0.0001729
11 Focal_adhesion_hsa04510 5 199 0.0001122 0.0005303
12 Wnt_signaling_pathway_hsa04310 4 146 0.0004132 0.00179
13 HIF_1_signaling_pathway_hsa04066 3 100 0.001782 0.007128
14 TNF_signaling_pathway_hsa04668 3 108 0.00222 0.008245
15 Ferroptosis_hsa04216 2 40 0.004151 0.01439
16 mTOR_signaling_pathway_hsa04150 3 151 0.005691 0.01741
17 Hedgehog_signaling_pathway_hsa04340 2 47 0.005692 0.01741
18 Jak_STAT_signaling_pathway_hsa04630 3 162 0.006909 0.01956
19 Necroptosis_hsa04217 3 164 0.007146 0.01956
20 NF_kappa_B_signaling_pathway_hsa04064 2 95 0.02186 0.05683
21 Sphingolipid_signaling_pathway_hsa04071 2 118 0.03264 0.08077
22 AMPK_signaling_pathway_hsa04152 2 121 0.03417 0.08077
23 Apelin_signaling_pathway_hsa04371 2 137 0.04281 0.09678
24 Tight_junction_hsa04530 2 170 0.06282 0.1361
25 Rap1_signaling_pathway_hsa04015 2 206 0.08753 0.1821
26 Cytokine_cytokine_receptor_interaction_hsa04060 2 270 0.137 0.274

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

MAGI2-AS3

 hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-let-7g-5p;hsa-miR-106b-5p;hsa-miR-151a-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-30d-3p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-320c;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-7-1-3p 22 CCND2 Sponge network -3.29 0.00119 -2.906 0 0.472
2 RP11-835E18.5 hsa-let-7a-3p;hsa-let-7a-5p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-miR-15a-5p;hsa-miR-195-5p;hsa-miR-1976;hsa-miR-32-3p;hsa-miR-34a-5p;hsa-miR-590-3p 10 CDK6 Sponge network -3.025 0.0156 -0.989 0.0001 0.426
3

MAGI2-AS3

 hsa-let-7a-3p;hsa-let-7a-5p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-193b-3p;hsa-miR-1976;hsa-miR-30d-3p;hsa-miR-30e-3p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-33b-5p;hsa-miR-378a-3p;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-671-5p;hsa-miR-7-1-3p 25 CDK6 Sponge network -3.29 0.00119 -0.989 0.0001 0.38
4

HAND2-AS1

 hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-148a-5p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-301a-3p;hsa-miR-486-5p;hsa-miR-576-5p;hsa-miR-629-5p;hsa-miR-940 12 IGF1 Sponge network -3.916 0.01209 -2.143 0 0.368
5 RP11-403I13.5 hsa-miR-125a-3p;hsa-miR-16-2-3p;hsa-miR-193b-3p;hsa-miR-26b-5p;hsa-miR-320a;hsa-miR-320b;hsa-miR-320c;hsa-miR-342-3p;hsa-miR-374a-5p;hsa-miR-374b-5p 10 PTEN Sponge network -0.107 0.94337 -0.844 0 0.357
6

HAND2-AS1

 hsa-miR-151a-3p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-338-3p;hsa-miR-421;hsa-miR-576-5p;hsa-miR-616-5p;hsa-miR-629-3p;hsa-miR-671-5p;hsa-miR-7-1-3p;hsa-miR-92a-3p;hsa-miR-940 16 THBS1 Sponge network -3.916 0.01209 -2.381 0 0.356
7

AGAP11

 hsa-miR-101-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-18a-3p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-20a-5p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-421;hsa-miR-501-5p;hsa-miR-93-5p 16 ZMAT3 Sponge network -1.068 0.03141 -0.352 0.09288 0.32
8

MAGI2-AS3

 hsa-let-7a-3p;hsa-let-7d-5p;hsa-let-7f-1-3p;hsa-miR-151a-3p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-616-5p;hsa-miR-671-5p;hsa-miR-7-1-3p;hsa-miR-92a-3p;hsa-miR-98-5p 15 THBS1 Sponge network -3.29 0.00119 -2.381 0 0.318
9

IGF2-AS

 hsa-let-7a-3p;hsa-let-7a-5p;hsa-let-7b-3p;hsa-let-7b-5p;hsa-miR-15a-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-193b-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-9-3p 13 CDK6 Sponge network -6.641 0.06774 -0.989 0.0001 0.316
10 DIO3OS hsa-miR-151a-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-331-5p;hsa-miR-589-3p 10 CCND2 Sponge network -4.106 0.02554 -2.906 0 0.313
11

HOXA-AS2

 hsa-let-7g-5p;hsa-miR-106a-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-191-5p;hsa-miR-19b-3p;hsa-miR-20b-5p;hsa-miR-320a;hsa-miR-33a-3p;hsa-miR-589-3p;hsa-miR-7-1-3p;hsa-miR-9-3p;hsa-miR-93-5p 16 CCND2 Sponge network -4.662 0.04704 -2.906 0 0.299
12

HAND2-AS1

 hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-151a-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-21-3p;hsa-miR-301a-3p;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-486-5p;hsa-miR-550a-5p;hsa-miR-616-5p;hsa-miR-7-1-3p;hsa-miR-93-5p 21 CCND2 Sponge network -3.916 0.01209 -2.906 0 0.293
13 RP11-822E23.8 hsa-miR-1254;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-193b-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-378a-3p 11 CDK6 Sponge network -5.123 0.10615 -0.989 0.0001 0.284
14

HOXA-AS2

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-191-5p;hsa-miR-195-5p;hsa-miR-200c-3p;hsa-miR-320a;hsa-miR-497-5p;hsa-miR-7-1-3p;hsa-miR-9-3p;hsa-miR-9-5p;hsa-miR-93-5p 14 CDK6 Sponge network -4.662 0.04704 -0.989 0.0001 0.283
15

RP11-166D19.1

 hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-193b-3p;hsa-miR-1976;hsa-miR-32-3p;hsa-miR-32-5p;hsa-miR-330-3p;hsa-miR-33b-5p;hsa-miR-378a-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-616-5p 16 CDK6 Sponge network -3.146 0.02178 -0.989 0.0001 0.265
16

C20orf203

 hsa-let-7g-5p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-151a-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-181a-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-191-5p;hsa-miR-19a-3p;hsa-miR-20a-5p;hsa-miR-20b-5p;hsa-miR-301a-3p;hsa-miR-3065-3p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-423-5p;hsa-miR-500a-5p;hsa-miR-501-5p;hsa-miR-548v;hsa-miR-550a-5p;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-7-1-3p;hsa-miR-93-5p 33 CCND2 Sponge network -2.387 0 -2.906 0 0.262
17

RFPL1S

 hsa-miR-107;hsa-miR-1254;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-1976;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-33b-5p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-491-3p;hsa-miR-501-3p;hsa-miR-7-1-3p;hsa-miR-9-3p;hsa-miR-92b-3p;hsa-miR-93-5p 20 CDK6 Sponge network -1.139 0.00508 -0.989 0.0001 0.253

Quest ID: 45174fdf77460615e6772a84331b6895